Global state: relapse medium term (3‐12 months) Clinical diagnoses · patients with schizophrenia or related psychoses
It is very uncertain whether PIMOZIDE changes global state: relapse medium term (3‐12 months) Clinical diagnoses compared with PLACEBO (very low certainty).
1 finding from 1 review
Mental state: presence of first‐rank symptoms medium term (3‐12 months) Clinical diagnoses · patients with schizophrenia or related psychoses
PIMOZIDE showed no clear difference in mental state: presence of first‐rank symptoms medium term (3‐12… compared with ANY ANTIPSYCHOTIC (low certainty).
1 finding from 1 review
Adverse effects: extrapyramidal adverse effectsParkinsonism (rigidity) short term (< 3 months) Clinical diagnoses · patients with schizophrenia or related psychoses
PIMOZIDE showed no clear difference in adverse effects: extrapyramidal adverse effectsParkinsonism… compared with ANY ANTIPSYCHOTIC (low certainty).
1 finding from 1 review
Adverse effects: extrapyramidal adverse effects Parkinsonism (rigidity) medium term (3‐12 months) Clinical diagnoses · patients with schizophrenia or related psychoses
1 finding from 1 review
Adverse effects: extrapyramidal adverse effects Parkinsonism (tremor) medium term (< 3 months) Clinical diagnoses · patients with schizophrenia or related psychoses
PIMOZIDE showed no clear difference in adverse effects: extrapyramidal adverse effects Parkinsonism… compared with ANY ANTIPSYCHOTIC (low certainty).
1 finding from 1 review
Quality of life: no significant change in quality of life/satisfaction medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mental state: no improvement medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mental state: presence of first‐rank symptoms medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: extrapyramidal adverse effects Parkinsonism (rigidity) short term (< 3 months) Extrapyramidal Symptom Rating Scale (ESRS) · patients with schizophrenia or related psychoses
It is very uncertain whether PIMOZIDE changes adverse effects: extrapyramidal adverse effects: Parkinsonism… compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects: extrapyramidal adverse effects Parkinsonism (rigidity) medium term (3‐12 months) Clinical diagnoses · patients with schizophrenia or related psychoses
It is very uncertain whether PIMOZIDE changes adverse effects: extrapyramidal adverse effects:Parkinsonism… compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects: extrapyramidal adverse effects:Parkinsonism (tremor) medium term (3‐12 months) Clinical diagnoses · patients with schizophrenia or related psychoses
It is very uncertain whether PIMOZIDE changes adverse effects: extrapyramidal adverse effects:Parkinsonism… compared with PLACEBO (very low certainty).
1 finding from 1 review
Quality of life: no significant change in quality of life/satisfaction medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global state: relapse medium term (3‐12 months) Clinical diagnoses · patients with schizophrenia or related psychoses
PIMOZIDE showed no clear difference in global state: relapse medium term (3‐12 months) Clinical diagnoses compared with ANY ANTIPSYCHOTIC (moderate certainty).
1 finding from 1 review
Mental state: no improvement medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses
It is very uncertain whether PIMOZIDE changes mental state: no improvement medium term (3‐12 months) As defined in… compared with ANY ANTIPSYCHOTIC (very low certainty).
1 finding from 1 review
Relief of pain · patients with trigeminal neuralgia
1 finding from 1 review
Reduction in pain intensity · patients with trigeminal neuralgia
1 finding from 1 review
Quality of life assessment 12 weeks after the start of treatment Not measured · patients with trigeminal neuralgia
1 finding from 1 review
Adverse effects The number of participants with adverse effects · patients with trigeminal neuralgia
1 finding from 1 review
Global state: relapse medium term (3‐12 months) Clinical diagnoses · patients with schizophrenia or related psychoses
PIMOZIDE + ANY ANTIPSYCHOTIC may leads to lower global state: relapsemedium term (3‐12 months) Clinical diagnoses compared with ANY ANTIPSYCHOTIC (low certainty).
1 finding from 1 review
Mental state: no improvement medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found